At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 331 enrolled
Drug / intervention
Fesoterodinedrug
Likely dose
Fesoterodine 4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12 Week, Multi-centre, Open Label Study To Evaluate The Efficacy, Tolerability And Safety Of A Fesoterodine Flexible Dose Regimen In Patients With Overactive Bladder.
In Brief
A Phase 4 clinical trial evaluating Fesoterodine for Urinary Bladder, Overactive. Completed, enrolled 331 participants across 39 sites.
Detailed Summary
To explore the effects of fesoterodine when used in a flexible dose manner
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder, Overactive
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2008
Enrollment StartFeb 2009
Primary CompletionJan 2010
TodayJul 2026
First PostedDec 10, 2008
Enrollment StartFeb 1, 2009
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 17.6 years ago
Interventions
Fesoterodinedrug
Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated